Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Autonomous & Electric Vehicles (DRIV) vs DexCom, Inc. (DXCM) Price & Performance

Global X Autonomous & Electric VehiclesTrade
DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

Global X Autonomous & Electric Vehicles vs DexCom, Inc. — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.66, while DexCom, Inc. trades at $72.58 (market cap $28.60B). The key difference: Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.

DRIVDXCM
Sector
Sector/ThematicHealth
52-Week High
$42.53$89.53
52-Week Low
$23.67$54.84
Market Cap
$28.60B
Enterprise Value
$27.57B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Autonomous & Electric Vehicles

DRIV trades at $35.37, down 3.2% on the day amid a bearish technical signal. The stock faces selling pressure with moving averages indicating a downtrend, though oversold RSI levels suggest potential near-term support. Recent news highlights strong global EV sales growth and China's aggressive expansion, providing a favorable industry backdrop for this electric vehicle-focused ETF.

The outlook remains cautious due to technical weakness, though industry momentum from rising EV adoption offers long-term growth potential. Key risks include regulatory uncertainty around Chinese vehicles and potential tariff impacts. Investors should monitor technical levels for stabilization signs amid volatile market conditions.

DexCom, Inc.

DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.

DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Autonomous & Electric Vehicles

DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.

Read more on DRIV

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM